Halozyme Therap

Forecast & Rating9 analysts currently cover Halozyme Therap, with about 77.8% giving a positive rating — meaning they expect the stock to rise. The average price target is $99.56, about 11.1% downside from the current price of $111.98. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 99.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Halozyme Therap closely still see room for the stock to rise. Data as of Oct 7, 2026; for reference only and not investment advice.